Merrimack Pharmaceuticals Story Overview

MACK -- USA Stock  

USD 9.50  0.42  4.63%

Macroaxis does not monitor all media channels or aggregates social signals for Merrimack Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Merrimack Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Merrimack Pharmaceuticals. Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance.
Acquisition by John Mendelsohn of 7500 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Filed transaction by Merrimack Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3

Merrimack Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by John Mendelsohn, the corporate stakeholder, on December 7, 2017. This event was filed by Merrimack Pharmaceuticals with SEC on 2017-09-15. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on December 7, 2017 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.95% . The trading delta at closing time when the story was published against the current closing price is 12.69% .

Similar stores for Merrimack Pharmaceuticals

3 days ago at www.macroaxis.com 
Acquisition by John Dineen of 7000 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Merrimack Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3
Heres Why These Two Are Trending USA Technologies, Inc. , Merrimack Pharmaceuticals, Inc.news
Analyst JournalFull coverage
over a week ago at http://santimes.com 
Financial Counselors Has Increased International Paper Co Position Last Week Merrimack Pharmaceuticals, Inc .....
news
San TimesFull coverage
over two weeks ago at http://huronreport.com 
Opus Investment Management Trimmed Paychex Stake Last Week Merrimack Pharmaceuticals, Inc. MACK ...
news
HuronReportSEC FORM 4 - SEC.gov SEC.govPoll 73 percent of US Workers Want DIY HR Tools, Many Small Employers Fall Short PR NewswireFull coverage
over three weeks ago at http://www.thestreetpoint.com 
That Will Motivate You Today- Orion Group Holdings, Inc. , Eaton Vance New York Municipal Income Trust ...
Thestreet News
The Stock Street Full coverage
over a month ago at http://yankeeanalysts.com 
What Are The Technicals Telling Us About Merrimack Pharmaceuticals Inc
news
Yankee AnalystsFull coverage
over a month ago at http://usindexlive.com 
On May, 9 The EPS for Merrimack Pharmaceuticals, Inc. Expected At -1.28
news
US Index LiveFull coverage
over a month ago at http://mostvolatilestocks.com 
Stock Performance Activity to Track Merrimack Pharmaceuticals, Inc.
news
MostVolatileStocks Full coverage
over a month ago at http://kgazette.com 
Analysts See -1.28 EPS for Merrimack Pharmaceuticals, Inc. Nfc Investments Lifted By 2.06 Million Its ...
news
Key GazetteFull coverage
over two months ago at http://mostvolatilestocks.com 
Analysts Call Attention Merrimack Pharmaceuticals, Inc.
news
MostVolatileStocks Full coverage
over two months ago at http://malibureport.com 
Is Merrimack Pharmaceuticals, Inc. a Buy The Stock Rises Again
news
The Malibu ReportMerrimack Pharmaceuticals, Inc. Increases to 8.29 on Apr, 7 US Index LiveMerrimack Pharmaceuticals Inc. Shares Rating Upgrade by Vetr Inc. BangaloreWeeklyFull coverage
over three months ago at http://ledgergazette.com 
-0.28 EPS Expected for Merrimack Pharmaceuticals Inc This Quarter
news
The Ledger Gazette - Feb 24, 2018 Merrimack Pharmaceuticals logo Wall Street analysts forecast that Merrimack Pharmaceuticals Inc will announce earnings per share of for the current quarter, Zacks reports.
over three months ago at http://news.cmlviz.com 
A New Kind of Stock Chart Merrimack Pharmaceuticals Inc NASDAQMACK ...
news
This is a real time view of the critical technical pivot points for Merrimack Pharmaceuticals Inc . The technical pivot points we look at all surround the stock price movement from the last 10-trading days through the last year.

Did you try this?

Run Equity Forecasting Now
   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Equity Forecasting

Current Asset

Current Asset Comparative Analysis
  Current Asset 
      Merrimack Pharmaceuticals Comparables 
Merrimack Pharmaceuticals is currently under evaluation in current asset category among related companies. Current Asset is all of company's assets that can be used to pay off current liabilities within current fiscal period or over next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Peers

Merrimack Pharmaceuticals Related Equities
VCEL  4.22 %   
0%
55.0%
VBLT  3.70 %   
0%
48.0%
DOVA  0.13 %   
0%
1.0%
DMTX  0.00 %   
0%
0%
DMPI  0.93 %   
12.0%
0%
DRRX  1.36 %   
17.0%
0%
DNLI  1.62 %   
21.0%
0%
NK  1.93 %   
25.0%
0%
DRNA  2.59 %   
33.0%
0%
VBIV  7.67 %   
100.0%
0%
Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance. Please also try Bollinger Bands module to use bollinger bands indicator to analyze target price for a given investing horizon.